Immix Biopharma, Inc. announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site. NXC-201 will be manufactured for each individual patient using the patient?s own T cells at its cellular immunotherapy manufacturing facility in California.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | -3.67% |
|
+19.19% | -65.90% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-65.90% | 62.34M | |
+4.57% | 97.7B | |
+5.66% | 41.43B | |
-12.80% | 32.85B | |
+80.99% | 29.33B | |
-15.53% | 15.47B | |
-8.70% | 12.89B | |
-12.22% | 11.51B | |
+183.25% | 10.74B | |
-55.41% | 8.97B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site